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Mitogen-activated protein kinase kinase 1 (MKK1), a dual-specificity tyrosine/threonine protein kinase, has
been shown to be phosphorylated and activated by the raf oncogene product as part of the mitogen-activated
protein kinase cascade. Here we report the phosphorylation and inactivation ofMKK1 by phosphorylation on
threonine 286 and threonine 292. MKK1 contains a consensus phosphorylation site for p34cdc2, a serine/
threonine protein kinase that regulates the cell division cycle, at Thr-286 and a related site at Thr-292. p34cdc2
catalyzes the in vitro phosphorylation of MKK1 on both of these threonine residues and inactivates MKK1
enzymatic activity. Both sites are phosphorylated in vivo as well. The data presented in this report provide
evidence that MKK1 is negatively regulated by threonine phosphorylation.
The regulation of mammalian cell growth is accomplished by
the integration of extracellular signals, such as polypeptide
growth factors, with intracellular phosphorylation cascades
extending from the plasma membrane to the cell nucleus.
Recent studies have indicated that mitogen-activated protein
(MAP) kinases (33, 41), also known as extracellular signal-
regulated kinases (7), are central to these intracellular signal
transduction pathways. Two MAP kinases, p42maPk and
p44mapk, have been well characterized in many mammalian cell
systems (33, 41). Both enzymes are phosphorylated on tyrosine
and threonine and are activated by a novel protein kinase
termed MAP kinase kinase (MKK), also known as MAP
kinase/extracellular signal-regulated kinase (MEK) kinase (9,
15, 29, 34, 37). The activity of MKK is specific for the
regulatory residues, threonine 183 and tyrosine 185, in p42maPk
(32), suggesting that MKK is a key regulator of MAP kinases
in the cell.
The regulation of the MKK/MAP kinase pathway is evolving
as a network of crosstalking protein kinases and phosphatases
that exert both positive and negative signals. For example, the
cellular proto-oncogene product, c-Raf-1, catalyzes the phos-
phorylation and activation of MKK (10, 11, 23). Furthermore,
the effects of other upstream protein kinases on MKK activity
are also becoming apparent. Several groups have demon-
strated a link between the MKK pathway and cyclic AMP-
dependent protein kinase (3, 8, 17, 39, 43). The latter protein
kinase is thought to negatively regulate the protein kinase
activity of c-Raf-1 (43), thus preventing further activation of
the MKK/MAP kinase pathway.
In addition to upstream negative regulation by protein
phosphorylation, negative control of the MKK pathway also
occurs at the MAP kinase level by dephosphorylation. A MAP
kinase-specific phosphatase that specifically removes both
types of regulatory phosphorylation has been documented (4).
MKK may also be subject to negative regulation by phos-
phatase action; treatment of active MKK with protein phos-
phatase 2A results in dephosphorylation and inactivation of
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protein kinase activity (9, 15, 29, 34, 36). Although this method
of inactivation has not been documented in vivo, observations
suggest that additional phosphorylation(s) of MKK occurs
following its initial activation and leads to increased suscepti-
bility to inactivation by phosphatase 2A in vitro (1). Taken
together, these observations demonstrate that both protein
kinases and phosphatases act upon MKK directly or indirectly
after its initial phosphorylation and activation to rigorously
control the activity of the MKK/MAP kinase pathway.
Recently, two isoforms of MKK, known as MKK1 and
MKK2, were identified, and their amino acid sequences were
elucidated (9, 31, 38, 45). MKK1 contains a consensus se-
quence for phosphorylation by p34cdc2, a key regulator of the
cell division cycle (5, 30), at Thr-286, as well as another, related
site at Thr-292. Active p34cdc2 kinase is a proline-directed
protein kinase that preferentially catalyzes the phosphoryla-
tion of serine or threonine in the sequence S/TP(X)nZ, where
n = 1 to 3 and Z is often lysine or arginine (28). Thr-286 and
Thr-292 are located within a large proline-rich insert in MKK1,
near the substrate binding domain (between domains IX and
X), suggesting a possible regulatory role for these potential
phosphorylation sites. Although MKK1 and MKK2 are highly
homologous, several important differences exist between these
enzymes: the amino acid at position 286 in MKK1 is valine in
MKK2, and the residue at position 292 in MKK1 is proline in
MKK2. On the basis of these observations, we evaluated the
potential regulation of mammalian MKK1 by p34cdc2 by testing
its ability to phosphorylate MKK1 and to modify its enzymatic
activity.
MATERIALS AND METHODS
Cell culture. HeLa cells were grown in suspension as previ-
ously described (27). HeLa cells were M phase arrested by
treating 5 x 105 cells per ml with 0.1 ,ug of nocodazole (Sigma,
St. Louis, Mo.) per ml for 20 h prior to lysis (27).
Recombinant and wild-type proteins. Baculovirus-expressed
MKK1 and MKK2, both containing a 12-amino-acid histidine
tag at the amino terminus, were activated by coexpression in
Sf9 insect cells with v-Raf or left unactivated. Both proteins
were purified from the Sf9 insect cell lysate by batch adsorption
to metal-chelating Sepharose (Pharmacia, Piscataway, N.J.)
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NEGATIVE REGULATION OF MKK1 1595
loaded with Ni2+. The resin was washed once with homogeni-
zation buffer (25 mM Tris-HCl [pH 7.9], 2 mM imidazole HCl
[pH 7.9], 10% glycerol, 1% Nonidet P-40 [NP-40], 500 mM
NaCl, 25 mM NaF, 1 mM Na3VO4, 1 mM P207, 1 mM
benzamidine, 1 mM phenylmethylsulfonyl fluoride [PMSF],
0.1% (-mercaptoethanol), once with homogenization buffer
without NP-40 and NaCl, and once with the latter buffer
containing 20 mM imidazole (pH 7.9). The MKK protein was
eluted from the resin with 250 mM imidazole, diluted approx-
imately 10-fold with H20, and applied to a Mono Q (Pharma-
cia) anionic-exchange column equilibrated with homogeniza-
tion buffer without NP-40 and NaCl. A linear NaCl gradient
(from 0 to 500 mM) was used to elute MKK from the resin.
MKK eluted at 125 to 150 mM NaCl and was stored at - 20°C
with 50% glycerol. Both the MKK1 and the MKK2 prepara-
tions were determined to be nearly homogenous by silver
staining and free of contaminating v-Raf by immunoblotting
with an anti-Raf antibody (data not shown). However, two
MKK2 proteins were identified by silver staining and by
immunoblotting, suggesting that the MKK2 preparation con-
tained a proteolytic MKK2 fragment.
Mitotic p34cdc2 kinase was purified to near homogeneity
from HeLa cells as previously reported (2, 27) and as described
briefly below. Cultured HeLa cells (32 liters) were treated with
nocodazole as described above to effect arrest in M phase. The
DNA content of the G2/M phase-blocked cells was confirmed
by fluorescence-activated cell sorter analysis. p34cdc2 kinase
activity was monitored throughout the purification with a
synthetic peptide as a substrate (H-ADAQHATPPKKKRKV
EDPKDF-OH) in kinase assays as described previously (2, 27).
The cells were harvested by centrifugation and lysed in 100 ml
of hypotonic buffer (10 mM sodium phosphate [pH 7.0], 10
mM NaF, 5 mM MgCl2, 1 mM EDTA, 10 mM ,3-glycerol
phosphate) by use of a Dounce homogenizer in the presence of
protease inhibitors. A 50% (NH4)2SO4 precipitate was pel-
leted and resuspended in 100 ml of buffer A (50 mM Tris-HCl
[pH 7.0], 5 mM MgCl2, 1 mM EDTA, 1 mM dithiothreitol, 10
mM (-glycerol phosphate). This solution was dialyzed against
1.5 liters of bufferA overnight at 4°C. On the following day, the
conductivity was adjusted to that of buffer B (same as buffer A
but containing 80 mM NaCI). The sample was then applied to
a DE52 (Whatman) column equilibrated with buffer B. The
unbound protein fraction was dialyzed overnight against 1 liter
of buffer 2 (50 mM N-2-hydroxyethylpiperazine-N'-2-ethane-
sulfonic acid [HEPES] [pH 7.0], 5 mM MgCl2, 1 mM EDTA,
1 mM dithiothreitol, 100 mM NaCl, 10% glycerol). Following
dialysis, the sample was applied to an S-Sepharose (Pharma-
cia) column equilibrated with buffer 2, and the protein was
eluted with a linear NaCl gradient (from 100 to 500 mM).
Fractions containing active p34cdc2 kinase were pooled and
diluted with buffer A until the conductivity reached that of
buffer B. This solution was applied to a 5-ml casein-Sepharose
column (5 mg of casein per ml) equilibrated with buffer B. A
linear NaCl gradient (from 80 to 500 mM) was used to elute
p34cdc2 kinase. The kinase activity peak was identified, and
fractions were pooled and adjusted to 80 mM NaCl with buffer
A. Q-Sepharose (Pharmacia) chromatography, with a linear
NaCl gradient (from 80 to 500 mM), was used to further
fractionate the protein sample. Again, p34cdc2 kinase was
identified, and fractions were pooled. The pooled activity was
concentrated with a 10,000-molecular-weight cutoff (Centri-
con; Amicon, Danvers, Mass.), and the concentrated proteins
were suspended with glycerol to 50%. The p34cdc2 and cyclin
proteins were found to be nearly homogenous by silver stain-
ing, and p34cdc2 kinase activity towards the substrate peptide
was linear over 30 min at 30°C. Both the Km and the Vm. of
this preparation were previously described (2, 27). The enzyme
was stored at - 20°C until needed. p34cdc2 kinase in this study
consists of the human 34-kDa catalytic subunit and mitotic p62
cyclin (2, 27).
Kinase-defective MAP kinase (K52R), containing a lysine-
to-arginine substitution at position 52, was previously de-
scribed (25).
Protein kinase assays. Each 40 RI of the kinase mixture (50
,uM ATP, 20 mM MgSO4, 1 mM DTT, 20 mM HEPES [pH
7.5], 5,000 cpm of [-y-32P]ATP per pmol) contained one or
more of the following: 100 ng of p34cdc2, 1 pug of MKK1, 2 ,ug
of K52R, or 4 pug of histone Hi (Sigma). MKK1 and p34cdc
were incubated together at 30°C for 12 min prior to the
addition of K52R. All reaction mixtures were then incubated at
30°C for 12 min, the reactions were stopped by the addition of
sodium dodecyl sulfate (SDS) sample buffer (24), and the
mixtures were subjected to electrophoresis on a 10% (wt/vol)
polyacrylamide gel in the presence of SDS. The gel was stained
with Coomassie blue and dried, and the labeled proteins were
visualized by autoradiography for 3.5 h at - 70°C.
Peptide synthesis. The MKK1 peptide, corresponding to
murine MKK1 residues 277 through 300, was synthesized on
an ABI (Foster City, Calif.) 430A peptide synthesizer and
purified by reverse-phase high-pressure liquid chromatography
(HPLC), and the molecular weight was verified by mass
spectral analysis on a mass spectrometer from Bio-Ion Inc.
(Uppsala, Sweden).
Phosphopeptide mapping and sequencing. High-voltage
electrophoresis-thin-layer chromatography (HVE/TLC) was
performed as previously described (12). In all cases, electro-
phoresis was along the horizontal axis and ascending hydro-
phobic chromatography was along the vertical axis with respect
to the origin. Each phosphorylated peptide was scraped off the
cellulose plate, eluted with pH 1.9 electrophoresis buffer (12),
covalently attached to an aryl amine-derivatized membrane
(Millipore, Bedford, Mass.), and subjected to repetitive cycles
of Edman degradation as described previously (12, 35).
For phosphopeptide sequencing, the MKK1 peptide (350
,uM) was phosphorylated by p34cdc2 under the kinase assay
conditions described above and purified from the kinase
reagents by reverse-phase HPLC. The phosphorylated peptide
was left undigested or digested for 4 h with 10 ,ug of trypsin
(Boehringer Mannheim Biochemicals, Indianapolis, Ind.) at
37°C and then incubated with an additional 10 ,ug of trypsin
overnight at the same temperature. Both samples were sub-
jected to HVE/TLC and repetitive Edman sequencing.
For phosphopeptide map comparisons, each sample was
phosphorylated as described above or isolated from 32p_
labeled HeLa cells by immunoprecipitation, digested with 10
,ug of thermolysin (Boehringer) in 50 mM ammonium bicar-
bonate, incubated at 37°C for 4 h, and subjected to HVE/TLC.
Immunoblotting and immunoprecipitation. An MKK1 pep-
tide antibody (R1) was generated in rabbits against the syn-
thetic peptide described above. Affinity-purified antibodies
were isolated on an MKK1 peptide column and shown to be
specific for MKK1 by immunoblotting and immunoprecipitat-
ing baculovirus-expressed MKK1 (data not shown). Antiserum
specific for p34cdc (G6) was generated in rabbits a ainst the
peptide carboxy terminus (11) of mammalian p34Cc2 kinase.
An STE7 antipeptide antibody was provided by Steve Pelech,
University of British Columbia. This antibody was generated
against a peptide sequence (H-FVGTSTYMSPERI-Cys) from
yeast STE7 and cross-reacts with mammalian MKK1 and
MKK2 at the sequence H-FVGTRSYMSPERL-OH (19, 44).
For direct immunoblotting of HeLa total cell lysate, approx-
imately 106 asynchronously growing HeLa cells were lysed with
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FIG. 1. Phosphorylation and inactivation of recombinant MKK1 by
p34cdc2. Lanes: 1 and 2, p34cdc2 and MKK1; 3 and 4, K52R and MKK1;
5 and 6, p34cdc2, K2R, and MKK1. The proteins identified in lanes 2,
4, and 6 were Coomassie blue stained, and the labeled proteins in lanes
1, 3, and 5 were visualized by autoradiography. The migration of each
protein is indicated to the right. Cyclin is labeled on the left.
SDS sample buffer (24). For all precipitations, the cells were
lysed in NP-40 lysis buffer (50 mM Tris [pH 7.4], 150 mM
NaCl, 1% NP-40, 10 mM EDTA, 10% glycerol, 1 mM
Na3VO4, 40 mM NaF, 100 pug of PMSF per ml, 1 pLg of
leupeptin per ml, 50 pLg of soybean trypsin inhibitor per ml, 100
pug of tolylsulfonyl phenylalanyl chloromethyl ketone [TPCK]
per ml, 4 mMp-nitrophenyl phosphate). Asynchronously grow-
ing HeLa cells (10 ) were metabolically labeled with 32p;
(NEN, Boston, Mass.) for 2 h (see below), and then MKK was
immunoprecipitated with 10 ,ug of RI antibody. SDS sample
buffer was used to elute immunoprecipitated MKK from the
antibody-protein A agarose (Pierce, Rockford, Ill.) complex.
The HeLa cell lysate and immunoprecipitated proteins were
subjected to electrophoresis on a 10% (wt/vol) polyacrylamide
gel containing SDS and transferred to nitrocellulose
(Schleicher & Schuell, Keene, N.H.). The filter was exposed to
film with an intensifying screen for 3.5 h at - 70°C. Following
film exposure, Rl was used to immunoblot the proteins on the
filter. Detection of Rl binding to MKK was accomplished with
a horseradish peroxidase-conjugated anti-rabbit IgG antibody
and chemiluminesence (ECL; Amersham, Arlington Heights,
Ill.). The filter was exposed to film for 1 min at room
temperature. The same exposure prior to immunoblotting did
not reveal any 32P-labeled proteins.
Rat MKK1 and rat MKK2 (100 ng each) were subjected to
SDS-polyacrylamide gel electrophoresis (PAGE) as described
above, transferred to nitrocellulose, probed with STE7 (1:1,000
dilution) or Ri (10 jig) antibody, and detected by use of ECL.
Precipitations of p34cdc2 were performed as described
above, except that 8 ,ul of G6 was used per p34cdc2 precipita-
tion. When necessary, all polyacrylamide gels were stained with
Coomassie blue to verify the protein levels loaded per lane
prior to exposure to film.
Cell labeling. Asynchronously growing HeLa cells were
washed several times in Dulbecco minimal essential medium
without phosphate (GIBCO, Grand Island, N.Y.), suspended
at 107 cells per ml in the same medium, and incubated at 37°C
for 1 h prior to labeling. 32p; was added to a 1-mCi/ml final
concentration and incubated at 37°C for 2 h with constant
mixing prior to lysis with NP-40 lysis buffer.
RESULTS
Phosphorylation of recombinant MKK1 by p34cdc2. To
determine whether active p34cdc2 kinase containing both the
catalytic and the cyclin subunits phosphorylated MKKi, a
baculovirus-expressed and enzymatically active rat fusion pro-
tein (MKK1) was used as an in vitro substrate in protein kinase
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FIG. 2. MKK1 inactivation is dependent upon the concentration of
p34cdc2 kinase. MKK1 was incubated with various amounts of p34cdc2
(from 0 to 1.8 ng; top of inset and abscissa) for 12 min prior to the
addition of K52R. Following an additional 12 min of incubation, the
reaction mixtures were subjected to SDS-PAGE. K52R was identified
by Coomassie blue staining and by autoradiography (inset). Each
protein band was excised from the gel, and Cerenkov radiation was
measured (ordinate).
assays (Fig. 1). In reaction mixtures containing both MKK1
and p34cdc2, MKK1 was detected as a 49-kDa phosphoprotein
(lane 1) that comigrated with a Coomassie blue-stained recom-
binant protein (lane 2). This phosphorylation was not detect-
able in samples containing p34cdc2 alone with [y-32P]ATP and
Mg, and in the absence of other protein kinases, MKK1 was
weakly autophosphorylated. The stoichiometry of MKK1 phos-
phorylation by p34cdc2 was determined to be approximately 1.7
mol of phosphate per mol of MKK1 (data not shown). An
additional phosphoprotein of 62 kDa was observed in samples
containing p34cdc2 (lanes 1 and 5); it corresponded to the
p34cdc2-associated p62 cyclin that is phosphorylated by p34cdc2
(2, 11, 27).
Inactivation of MKK1 by p34cdc2. To evaluate the effects of
p34cdc2 on MKK1 function, it was necessary to include a
specific substrate for MKK, namely, p42mpPk. However, wild-
type p42maPk has been shown to be autophosphorylated on
tyrosine (36, 46). To avoid any interference by autophosphor-
ylation, a mutant of p42maP (K52R) that is defective for
protein kinase activity (25, 34) was used as a substrate to
measure MKK1 activity (Fig. 1, lane 3). When p34cdc2 was
preincubated with MKK1 prior to the addition of K52R,
phosphorylation of K52R failed to occur (lane 5), even though
the amounts of K52R and MKK1 present in the reaction (lane
6) were equal to those present in the MKK1-K52R control
(lane 4). This result suggested that MKK1 phosphorylation by
p34cdc2 inactivated the enzyme. To further test this conclusion
and to exclude other explanations, several additional experi-
ments were performed: (i) p34cdc2 did not phosphorylate
K52R; (ii) when p34cdc2 was incubated alone, only p62 cyclin B
became phosphorylated; and (iii), as expected, K52R was not
autophosphorylated. Also, since no v-Raf was identified in our
preparations (see Materials and Methods), the observed result
cannot be attributed to an interaction between p34cdc2 and
v-Raf.
Further control experiments demonstrated that MKK1 was
enzymatically inactivated by p34cdc2 kinase and that the inac-
tivation was not an artifact attributable to contaminating
agents. When the p34cdc2 concentration in the inactivation
assay was varied, the degree to which K52R phosphorylation
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FIG. 3. p34cdc2 does not catalyze the phosphorylation or inactivation of MKK2. (A) Comparison of the rat MKK1 and rat MKK2 amino acid
sequences between kinase domains IX and X. Thr-286 and Thr-292 are indicated by arrows above the sequence. Dashes indicate gaps inserted to
properly align the sequences. (B) Graphic representation of the K52R and histone Hi kinase assays. Following incubation of the assay components
(listed below each bar on the abscissa), the kinase assays (see Materials and Methods) were stopped with SDS sample buffer, and samples were
subjected to electrophoresis through a 10% polyacrylamide gel. K52R and histone Hi were identified by Coomassie blue staining and
autoradiography. The proteins were excised from the gel, and Cerenkov radiation was counted. This is a representative result of three separate
assays. The ordinate shows counts incorporated into K52R or histone Hi per minute (103). All protein components are described in the text. Inact.,
inactivated.
was reduced was linearly dependent upon the amount of
p34cdc2 present (Fig. 2). Furthermore, heat inactivation of
p34cdc2 prior to its addition to the kinase reaction failed to
inhibit the phosphorylation of K52R by MKK1. This result
argues that the observed inactivation of MKK1 is enzymatic
and is not caused by a contaminant within the p34cdc2 prepa-
ration.
Small amounts of CDC25, a tyrosine/threonine phosphatase,
have been documented to be complexed with p34C c%yclin
(14); therefore, this or other phosphatases could be responsi-
ble for the observed MKK1 inactivation. To address this issue,
various phosphatase inhibitors were included in the MKK1
inactivation assay. The addition of the phosphatase inhibitors 1
mM sodium vanadate, 4 mM p-nitrophenyl phosphate, and 1
,uM okadaic acid to the reaction mixtures failed to prevent
MKK1 inactivation (data not shown). These results demon-
strate that the inactivation of MKK1 is not attributable to the
removal of the activating phosphate by a contaminating phos-
phatase within the p34 c preparation.
p34dc2 does not inactivate MKK2. Recently, the cloning and
sequencing of rat MKK2 were reported (44). MKK1 and
MKK2 are highly conserved throughout most of their amino
acid sequences but diverge significantly near the amino termi-
nus and between kinase domains IX and X (Fig. 3A), the
region containing Thr-286 and Thr-292 in MKK1. Since both
threonines are absent in MKK2 and both represent potential
p34cdc2 phosphorylation sites on MKK1, we used baculovirus-
expressed MKK2 (preactivated with v-Raf and purified) con-
taining a 12-residue histidine tag at the amino terminus to
evaluate the ability of p34cdc2 to catalyze the in vitro phosphor-
ylation and inactivation of MKK2. Representative kinase as-
says with K52R or histone Hi as a substrate are graphically
presented in Fig. 3B. Both MKK1 and MKK2 catalyzed the
phosphorylation of K52R (bars 1 and 2). MKK1 (bar 3) but not
MKK2 (bar 4) was inactivated by p34cdc2 kinase. In agreement
with this result, p34cdc2 did not catalyze the in vitro phosphor-
ylation of MKK2 (data not shown). As expected, control
experiments demonstrated that enzymatically inactivated
MKK1 and MKK2 did not catalyze the phosphorylation of
K52R (bars 5 and 6) and that the p34cdc2 preparation did not
catalyze the enzymatic activation of MKK1 and MKK2 (bars 7
and 8, respectively). The p34cdc2 preparation did not phosphor-
ylate K52R (bar 9) but did catalyze the phosphorylation of
histone Hi (bar 10). Since p34cdc2 did not catalyze the
phosphorylation or inactivation of MKK2, these data indicate
that MKK1 inactivation is catalyzed by p34cdc2 and further
demonstrate that MKK1 inactivation is not the result of a
contaminating phosphatase within the p34cdc2 preparation.
Phosphorylation of a synthetic peptide that contains Thr-
286 and Thr-292 by p34cdc2. To determine whether Thr-286
was phosphorylated by p34cdc2, a synthetic peptide correspond-
ing to MKK1 residues 277 through 300 (1, 9, 38, 45) was used
as a substrate in kinase assays. Phosphorylation of the peptide
was linear with substrate concentration. The Km for MKK1
peptide phosphorylation by p34cdc2 was determined to be
approximately 125 ,uM; the VmS, was 1,388 nmol/min/mg (data
not shown).
Phosphoamino acid analysis was performed following the
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FIG. 4. Identification of p34cdc2 phosphorylation sites within undigested (A) and trypsin-treated (B) synthetic MKKI peptide by repetitive
Edman degradation on an ABI 473A protein sequencer. The insets in panels A and B are two-dimensional phosphopeptide maps of undigested
and trypsin-generated phosphopeptides, respectively. Origins are represented by *, and the electrophoretic dimensions are indicated by + and -.
The hydrophobic chromatography dimension extends upwards from the origin. Thr-286 and Thr-292 are labeled in each panel by an asterisk, and
the trypsin cleavage site is marked by an arrow in panel B. Abscissa, corresponding peptide residue. Ordinate, counts per minute released following
each cleavage cycle. The "blob" just below and to the right of spot 3 represents an artifact of autoradiography.
phosphorylation of the synthetic peptide by p34cdc2, and only
phosphothreonine was detected (data not shown). To deter-
mine the site of phosphorylation, the phosphorylated peptide
was subjected to two-dimensional HVE/TLC (Fig. 4A, inset),
elution, and repetitive Edman degradation. Phosphate release
from the sequencer corresponded to Thr-286 (cycle 10) being
the predominant site of threonine phosphorylation by p34cdc2
(Fig. 4A). However, the phosphate level did not return to the
baseline, suggesting that Thr-292 was also phosphorylated. To
test this hypothesis, the phosphorylated peptide was proteo-
lytically cleaved with trypsin and subjected to HVE/TLC (Fig.
4B, inset). Two novel phosphopeptides were identified and
subjected to sequence analysis for the release of 32P-labeled
residues. Phosphopeptide 2 contained phosphorylated Thr-
286, and phosphopeptide 3 contained phosphorylated Thr-292
(Fig. 4B). The amino acid sequence of phosphopeptide 3 was
confirmed by repetitive Edman degradation and an analysis of
amino acid residues at each cycle independently of the phos-
phopeptide sequence (data not shown).
Phosphopeptide mapping of MKK1. p34CdK2_phosphorylated
MKK1 (Fig. 1, lane 1) was digested with thermolysin and
subjected to two-dimensional phosphopeptide mapping (Fig.
5A). Two predominant phosphopeptides, one major and one
minor (labeled ot and 3, respectively), were observed. Several
additional minor phosphopeptides, possibly reflecting incom-
plete digestion, were also identified.
Phosphopeptide mapping was also performed on the ther-
molysin-treated synthetic MKK1 peptide phosphorylated by
p34cdc2 (Fig. 5B). Two phosphopeptides (labeled 1 and 2) were
identified. Both migrated, with respect to the origin, in posi-
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FIG. 5. Mapping of MKK1 phosphopeptides. (A) Recombinant
MKK1. (B) Synthetic MKK1 peptide. (C) Mixture of panels A and B.
0, origin. The electrophoretic (Electro.) dimensions are indicated by
+ and -, and the ascending chromatography (Chrom.) dimension is
indicated by the arrow to the right of panels B and C).
tions similar to those of phosphopeptides a and 3 identified in
Fig. 5A. To determine the relationship of phosphopeptides 1
and 2 to phosphopeptides a and 3, samples identical to those
in Fig. 5A and B were mixed and subjected to phosphopeptide
mapping (Fig. 5C). Phosphopeptides 1 and 2 comigrated with
phosphopeptides a and ,B, respectively. Thus, MKK1 appears
to be phosphorylated by p34c c2 on the site corresponding to
the synthetic MKK1 peptide. Since MKK1 is phosphorylated
on both Thr-286 and Thr-292, phosphopeptide a is likely to
contain both of these sites phosphorylated, while phosphopep-
tide , may be a singly phosphorylated form.
Identification ofMKK in HeLa cell extracts. MKK1-specific
antisera were raised in rabbits against the above-mentioned
synthetic MKK1 peptide, and the corresponding antibodies
were affinity purified for use in identifying MKK1. To deter-
mine the antibody specificity, recombinant MKK1 and MKK2
were subjected to SDS-PAGE and immunoblotted with the Rl
antibody (Fig. 6). In addition, identical samples were immu-
noblotted with an antibody to STE7 (see Materials and Meth-
ods), a yeast MKK homolog (13). The STE7 antibody reacts
with an epitope that is conserved among known MKKs. The
STE7 antibody reacted with both MKK1 and MKK2 (left
panel), but only MKK1 was detected by the Rl antibody (right
panel).
To expand our studies of MKK1 inactivation in vivo, it was
necessary to identify and precipitate the protein from cell
lysates so that its phosphorylation state could be determined.
Therefore, we used the Rl antibody to immunoblot HeLa cell
lysates (Fig. 7). Ri reacted with a 45-kDa protein doublet in
lysates from HeLa cells growing asynchronously (third lane,
arrows). It also immunoprecipitated and immunoblotted sim-
ilar proteins (second lane) from the same cells labeled with
32pi, and both proteins were phosphorylated (first lane). Thus,
at least two MKK1 phosphoproteins or differentially phosphor-
ylated forms exist in the asynchronous HeLa cell population.
Furthermore, the protein with the slower SDS gel mobility
reproducibly predominated in M phase-blocked HeLa cells
STE7 Ab MKK1 Ab
FIG. 6. MKK1 antibody specificity. Two samples each of rat MKK1
and rat MKK2 (100 ng) were subjected to electrophoresis on a 10%
polyacrylamide gel and transferred to nitrocellulose. One set of
proteins was immunoblotted with an antibody STE7 (left panel), and
one set was immunoblotted with the MKK1 (R1) antibody (right
panel). The protein contained in each lane is given above the lane, and
MKK1 and MKK2 are indicated to the left by arrows. Molecular mass
standards are given on the right.
(fourth lane, right arrow), suggesting that the lower form may
be cell cycle regulated. Additional proteins of higher molecular
masses were identified by Rl in both the immunoprecipitation
lane (second lane) and the SDS cell lysate lanes (third and
fourth lanes), but the identities of these proteins are currently
unknown.
Phosphopeptide mapping of MKK labeled in vivo. In con-
tinuing our efforts to identify the in vivo phosphorylation sites
of MKK1, both 32P-labeled phosphoproteins identified above
were eluted separately from the polyacrylamide gel, digested
with thermolysin, and subjected to HVE/TLC (Fig. 8). Two
phosphopeptides that were identified for the lower phospho-
protein (Fig. 8A, labeled y and 8) did not comigrate with the
p34cdc2-phosphorylated thermolysin-treated synthetic peptide
(Fig. 8B, labeled 1). Three thermolysin-generated phos-
a_
cn
CL aL Lysate
Cl) 0E < z
-_W
*- U
-.
V
a MKK
FIG. 7. Identification of MKK in asynchronously growing (Asyn)
and nocodazole-blocked (Noco) HeLa cells. Lanes: first, direct expo-
sure of the immunoprecipitate (IP) from 32P-labeled HeLa cells in the
second lane to film; second, MKK doublet immunoprecipitated and
then immunoblotted with the MKK1 antibody (Rl); third, MKK
doublet identified in an SDS cell lysate from asynchronously growing
HeLa cells; fourth, nocodazole-blocked HeLa cell lysate. The first and
second lanes were subjected to electrophoresis separately from the
third and fourth lanes.
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FIG. 8. HeLa cell MKK phosphopeptide maps. (A) Lower MKK
phosphoprotein. (B) Lower MKK phosphoprotein mixed with syn-
thetic MKK phosphopeptide. (C) Upper MKK phosphoprotein. (D)
Upper MKK phosphoprotein mixed with synthetic MKK phosphopep-
tide. The migration of the synthetic phosphopeptide is marked by an
arrowhead in panels B and D. The electrophoretic (Electro.) and
chromatography (Chrom.) dimensions are labeled by arrows. 0,
origin. Panels A and C were exposed with an intensifying screen at
- 70°C for 15 h. Panels B and D were exposed for 7.5 h to minimize
exposure background.
phopeptides were identified for the upper phosphoprotein
(Fig. 8C, labeled a-, y, and 8); the cx phosphopeptide comi-
grated with the phosphorylated MKK1 peptide (Fig. 8D,
labeled 1/ox). These data suggest that the lower MKK phos-
phoprotein does not contain the p34cdc2 phosphorylation
site(s) or that the site(s) is not phosphorylated but that the
upper MKK phosphoprotein does contain the site(s) phosphor-
ylated in vivo. Furthermore, the similarity of the phosphopep-
tide maps of the upper and lower phosphoproteins (Fig. 8A
versus 8C) suggest that these proteins are closely related or
possibly identical.
In summary, p34CdC 2-phosphorylated recombinant MKK1
and 32P-labeled MKK isolated from asynchronous HeLa cells
both contain a thermolysin-generated phosphopeptide that
comigrates in two-dimensional thin-layer chromatography with
a synthetic MKK1 peptide phosphorylated by p34cdc2 on
Thr-286 and Thr-292. This result suggests that the recombinant
MKK1 protein and the in vivo-isolated MKK protein are
phosphorylated on these sites and that MKK1 may be subject
to the same negative regulation in vivo.
DISCUSSION
The results presented here indicate that the phosphorylation
of MKK1 on Thr-286 and Thr-292 by p34cdc2 in vitro will
inhibit MKK protein kinase activity but that p34cdc2 will not
catalyze the in vitro phosphorylation and inactivation of
MKK2. Since Thr-286 and Thr-292 are absent in MKK2, these
sites are likely to be responsible for the negative regulation of
MKK1. The phosphorylation of MKK1 might inactivate kinase
activity by altering MAP kinase binding to the molecule.
Residues Thr-286 and Thr-292 are contained within an unusu-
ally proline-rich segment (residues 262 to 307) containing 11
prolines out of 45 residues (1, 9, 38, 45). A comparison of the
MKK1 amino acid sequence with the amino acid sequence and
structure of cyclic AMP-dependent protein kinase shows that
the residues between MKK1 domains IX and X form a loop
structure just below the enzymatic cleft (21). This region of
MKK is much larger than those of other protein kinases; 10 or
11 residues are typical of many protein kinases (18), but MKK
contains 49 residues in this region. This feature might impart
the unique specificity of MKK for both p42maPk and p44maPk,
and phosphorylation might alter this enzyme-substrate inter-
action. Since MKK1 and MKK2 do not share significant
homology in this region (13 of 32 residues are shared) and only
MKK1 contains the p34cdc2 phosphorylation sites, MKK1 and
MKK2 are likely to be regulated differently in vivo.
These findings are important to MKK1 regulation and to the
regulation of the entire p42naPk cascade because they imply
that a ne ative feedback mechanism controls MKK1 activity.
The p34c 2-catalyzed phosphorylation of MKK1 in vitro over-
rides the activating phosphorylation that can be accomplished
by Raf (10, 20, 23). Since HeLa cell MKK1 is phosphorylated
on the same threonine residues whose phosphorylation is
catalyzed by p34cdc2 kinase in vitro and this phosphorylation
causes the enzymatic inactivation of MKK1, MKK1 could be
negatively regulated by these phosphorylations in vivo as well.
Furthermore, there exists in asynchronous HeLa cells a form
of MKK that is not phosphorylated on the inactivation site(s).
Given the specificity of the Rl antibody for MKK1, this protein
probably represents the active MKK1 form.
Does p34cdc2 kinase catalyze the phosphorylation and inac-
tivation of MKK1 in vivo? It is of interest to speculate that the
inactivating MKK1 phosphorylation(s) may only occur during
the cell cycle when p34C c2 kinase is most active to prevent an
untimely activation of the MKK/MAP kinase pathway. Our
data support this hypothesis by demonstrating that the upper
MKK1 phosphoprotein, which contains the inactivation sites
phosphorylated, predominates during M phase, when p34cdc2 is
most active. Furthermore, M phase-blocked HeLa cells do not
contain active MKK and p42maPk (data not shown). In support
of this idea, Tamemoto et al. failed to identify active MAP
kinase in nocodazole-treated CHO cells or in M-phase CHO
cells prepared by mechanically shaking the M-phase cells off
the culture plate (42). On the basis of these observations, we
propose that during mitosis, threonine 286 and threonine 292
serve to inhibit MKK1 activity and suppress the MAP kinase
pathway.
The protein kinase responsible for the in vivo phosphoryla-
tion of MKK1 remains to be demonstrated unequivocally.
However, the phosphorylation of MKK1 by mitotic p34cdc2
kinase in vitro suggests that during M phase, this enzyme could
be responsible for the corresponding in vivo phosphorylations
identified in HeLa cell MKK. During the start ofM phase, the
physical barriers blocking an interaction between these protein
kinases is eliminated once the nuclear envelope breaks down.
Therefore, a direct association of p34cdc2 kinase and MKK1
would be possible at this point in the cell division cycle.
Although the data presented here suggest that mitotic p34cdc2
kinase could be responsible for the in vivo phosphorylation
during M phase, we currently do not know what the phosphor-
ylation state of MKK1 is during G1/S, S, or G2 of the cell
division cycle.
During the GJGl transition, the position of the cell cycle at
which MKK and p42maPk become transiently activated, p34cdc2
kinase is not active and possibly not capable of a direct
interaction with MKK because of localization differences.
These limitations suggest that the inactivating MKK phosphor-
ylation(s) may not occur or may be carried out by a p34cdc2_
related kinase active in Gl. Although Thr-292 represents an
ideal MAP kinase phosphorylation site (6), p42maPk can prob-
ably be ruled out as a potential negative feedback regulator of
MKK1 during GJGI because of a poor MKK1 phosphoryla-
tion Km and weak inhibitory effects upon MKK1 (data not
shown). Further experiments are also necessary to address all
of these issues more thoroughly.
Several observations suggest that p42maPk regulation is com-
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plex and varies, depending upon the cell system and activating
agent. Injection of active p34cdc2 (16) or 7clins (26) into
Xenopus oocytes results in sustained p42maP activity, which
rapidly decreases upon fertilization, suggesting that p34cdc2
acts upstream of p42maPk. However, injection of cyclins into
clam oocytes fails to activate p42maPk but does cause p34cdc2
activation (40). These observations suggest that p42maPk pro-
teins from Xenopus and clam oocytes are not functional
homologs and/or that they are regulated differently. Therefore,
multiple MKK-related enzymes may differentially regulate
p42maPk activity, depending upon the cell type and/or activating
agent. Supporting this hypothesis, MKK clones which lack
Thr-286 and Thr-292 have been isolated from a rat cDNA
library (44), and cloned Xenopus oocyte MKK does not contain
these phosphorylation sites (22). Thus, p42maPk feedback
mechanisms acting through MKK may depend upon the MKK
isoforms present in the stimulated cell.
The demonstration in this report that MKK1 can be phos-
phorylated and inactivated in vitro by p34cdc2 and the identi-
fication of the same MKK phosphorylations in vivo provide
evidence that p34cdc2 kinase could modulate the activity of
extracellular signal-regulated protein kinases. Existing para-
digms of growth factor action strive to describe the mecha-
nisms by which these external signals stimulate cell division.
Our data expand this paradigm by suggesting that cell division
negatively affects the growth factor-activated protein kinase
cascade.
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